This activity is supported by an unrestricted medical contribution from Sanofi. Procedures for further independent support are ongoing.
Minimal Residual Disease (MRD) is emerging as a powerful prognostic marker in multiple myeloma. Advancing knowledge of MRD can support personalised treatment, improve patient outcomes, and facilitate the development of more effective therapeutic strategies.
AstraZeneca and Gilead have provided sponsorship grants towards this independent activity.
The increasing awareness of health disparities has brought to light the urgent need to promote equity in cancer care. Social determinants of health play a critical role in shaping outcomes for patients, caregivers, and healthcare professionals. Advancing health equity in oncology requires identifying and addressing these systemic barriers, expanding access to high-quality care, and ensuring that every patient receives the treatment they need and deserve.
Developed in collaboration with Pfizer
Personalised diagnostic tests are essential in tailoring prostate cancer care, leveraging unique molecular features such as gene alterations and protein expression for treatment selection and prognosis. SPCC hosted a closed task force (12 June 2025); the most important outcomes of the task force will be summarised in a manuscript that will be submitted for publication to a peer reviewed journal.
Supported by a grant from Eli Lilly & Company
Sharing Progress in Cancer Care and Lilly are collaborating and seeking grant proposals in support of improving care of Early Breast Cancer (EBC) patients in Europe.
Supported by Fresenius Kabi
Considering the importance of nutritional status in Geriatric Oncology, Sharing Progress in Cancer Care is carrying out a targeted project.
Supported by a grant from Pfizer Global Medical Grants
Seven projects have been selected following the European request for proposals sponsored by Pfizer Global Medical Grants in partnership with SPCC. The initiative is now entering the operational project execution stage that will play out over the next two years.
Supported by Fresenius Kabi and Helsinn Healthcare SA
Over the last years cancer care has seen a lot of developments regarding multidisciplinary approaches and the term patient-centered care has been proposed to encompass both supportive and palliative care.